Aurelia Nicoleta Cristea 1, B. S. Velescu 2
1 Profesor universitar, doctor în ştiinţe farmaceutice
2 Preparator universitar, doctorand
Abstract
This paper represents a review of the up-to-date knowledge about endogenous cannabinoid system (SCBE): pharmacological implications correlated with mechanism type (agonist, antagonist, endocannabinoid metabolize catalyzing enzymatic systems inhibitor), pharmacotherapeutic perspectives, as well as the new drugs with mechanisms on this system (rimonabant, nabilona, dronabinol), from pharmacological and therapeutical view point. New data on SCBE, opened a new possible view for the treatment of some nervous disorders (melancholic depression, epilepsy, neurodegenerative disorders as Parkinson and Alzheimer diseases), immune disorders (multiple sclerosis, Crohn´s disease), cardiovascular disorders (stroke, arterial hypertension, myocardial infarction), neuropathic pain, inflammation and cancer of immune origin. In a previous paper of this journal, the receptors, endocannabinoids, physiological functions, pathological implications and correlations with other signaling systems were presented.